Brief: Nicox Selects 0.1% NCX 470 Dose In Mont Blanc Phase 3 Glaucoma Trial

Nicox SA

23/09/2020 17:08

Sept 23 (Reuters) - NICOX SA  NCOX.PA :
    * NICOX SELECTS 0.1% NCX 470 DOSE IN ADAPTIVE STAGE OF MONT
BLANC
PHASE 3 GLAUCOMA TRIAL
    * DOSE SELECTION ENABLES SECOND PART OF MONT BLANC PHASE 3
TRIAL
WITH A 1:1 HEAD-TO-HEAD COMPARISON VERSUS LATANOPROST
    * DOSE SELECTION ALSO ENABLES START OF DENALI, SECOND NCX
470
PHASE 3 TRIAL, BEFORE END OF YEAR
    * AT CURRENT RECRUITMENT RATES, TOP-LINE RESULTS FROM MONT
BLANC
ARE EXPECTED IN Q4 2021

Source text for Eikon:  ID:nGNE64SY9w 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))